MAPT and Alzheimer disease: A previous study showed that blocking the activity of EP3 ameliorates the effects of PGE2 in impairing hippocampal presynaptic plasticity and identified EP3 as a potential therapeutic target for AD (Maingret et al., 2017) and another study showed that EP3 is critical for the phosphorylation of tau (Guan and Wang, 2018).